A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas

NCT06303570 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Dercum's Disease

Interventions

DRUG: CBL-514 injection
DRUG: 0.9% Sodium chloride

Sponsor

Caliway Biopharmaceuticals Co., Ltd.